Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves Morris Water Maze Performance in Aged Rats

John J. Alam

• Equity:

  I am the founder and majority owner of EIP Pharma, the company that funded the study.
  Sponsors:

  I am founder and CEO of EIP Pharma. I do not receive a salary or other compensation from EIP Pharma.
  Patents/Royalties

  I am the inventor of a patent on the use of VX-745 to reduce amyloid plaque load (US patent #8,697,627) that has been assigned to EIP Pharma.